Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Atria Investments LLC

Atria Investments LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 29.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,987 shares of the medical instruments supplier’s stock after purchasing an additional 3,204 shares during the quarter. Atria Investments LLC’s holdings in Becton, Dickinson and were worth $3,448,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Dorsey & Whitney Trust CO LLC increased its position in shares of Becton, Dickinson and by 1.6% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 2,535 shares of the medical instruments supplier’s stock worth $675,000 after purchasing an additional 41 shares during the last quarter. Capital Asset Advisory Services LLC grew its position in Becton, Dickinson and by 3.1% in the 2nd quarter. Capital Asset Advisory Services LLC now owns 1,433 shares of the medical instruments supplier’s stock valued at $353,000 after acquiring an additional 43 shares in the last quarter. Armor Investment Advisors LLC grew its position in Becton, Dickinson and by 0.5% in the 1st quarter. Armor Investment Advisors LLC now owns 8,319 shares of the medical instruments supplier’s stock valued at $2,213,000 after acquiring an additional 44 shares in the last quarter. McIlrath & Eck LLC grew its position in Becton, Dickinson and by 44.9% in the 1st quarter. McIlrath & Eck LLC now owns 142 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 44 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC grew its position in Becton, Dickinson and by 1.7% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 3,051 shares of the medical instruments supplier’s stock valued at $811,000 after acquiring an additional 50 shares in the last quarter. 86.74% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Price Performance

BDX stock opened at $225.59 on Monday. The business has a 50 day moving average price of $231.12 and a 200 day moving average price of $243.49. The stock has a market cap of $64.34 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 2.59 and a beta of 0.61. Becton, Dickinson and Company has a fifty-two week low of $215.90 and a fifty-two week high of $280.62. The company has a quick ratio of 0.63, a current ratio of 1.04 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and (NYSE:BDXGet Rating) last posted its earnings results on Thursday, November 10th. The medical instruments supplier reported $2.75 earnings per share for the quarter, topping the consensus estimate of $2.74 by $0.01. The firm had revenue of $4.76 billion during the quarter, compared to analysts’ expectations of $4.72 billion. Becton, Dickinson and had a return on equity of 14.47% and a net margin of 9.16%. The firm’s revenue was down 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.15 earnings per share. Equities research analysts anticipate that Becton, Dickinson and Company will post 11.94 earnings per share for the current fiscal year.

Becton, Dickinson and Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 30th. Shareholders of record on Friday, December 9th will be paid a $0.91 dividend. The ex-dividend date is Thursday, December 8th. This represents a $3.64 dividend on an annualized basis and a yield of 1.61%. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.87. Becton, Dickinson and’s payout ratio is currently 59.18%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BDX. Cowen dropped their target price on Becton, Dickinson and to $255.00 in a research report on Wednesday, November 16th. William Blair reaffirmed an “outperform” rating on shares of Becton, Dickinson and in a research report on Friday, November 11th. Citigroup dropped their target price on Becton, Dickinson and from $227.00 to $220.00 in a research report on Monday, November 14th. The Goldman Sachs Group lifted their price objective on Becton, Dickinson and from $278.00 to $319.00 and gave the company a “buy” rating in a research note on Tuesday, August 16th. Finally, Piper Sandler decreased their price objective on Becton, Dickinson and from $255.00 to $245.00 and set a “neutral” rating for the company in a research note on Thursday, November 10th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and has an average rating of “Hold” and a consensus target price of $272.40.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.